Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 24 results for gabapentin

  1. Dupilumab for treating moderate to severe prurigo nodularis (TA955)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.

  2. Bipolar disorder: assessment and management (CG185)

    This guideline covers recognising, assessing and treating bipolar disorder (formerly known as manic depression) in children, young people and adults. The recommendations apply to bipolar I, bipolar II, mixed affective and rapid cycling disorders. It aims to improve access to treatment and quality of life in people with bipolar disorder.

  3. Difelikefalin for treating pruritus in people having haemodialysis (TA890)

    Evidence-based recommendations on difelikefalin (Kapruvia) for pruritus in adults with chronic kidney disease having haemodialysis.

  4. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  5. Epilepsies in children, young people and adults (NG217)

    This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.

  6. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (NG215)

    This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.

  7. Headaches in over 12s: diagnosis and management (CG150)

    This guideline covers advice on the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.

  8. Cenobamate for treating focal onset seizures in epilepsy (TA753)

    Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.

  9. NICE calls for healthcare professionals to use shared decision making best practice to highlight the risks of medicines associated with dependence

    NICE is advising doctors, nurses and pharmacists to discuss with patients the risks of prescribing them medicines including opioids, sleeping pills and antidepressants.

  10. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

  11. What is the clinical and cost effectiveness of opioids for the management of acute sciatica?

    knowledge of the potential longer-term harms, and the reclassification of gabapentin and pregabalin as Schedule 3 controlled drugs...

  12. Low back pain and sciatica in over 16s: assessment and management (NG59)

    This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.

  13. Medicines Optimisation for Neuropathic Pain

    2013. NICE recommends offering a choice of amitriptyline, duloxetine, gabapentin or pregabalin as initial treatment for neuropathic...

  14. What is the most clinically and cost-effective timing and dose of a single administration of gabapentin to relieve pain in people undergoing surgery whose pain is expected to be moderate to severe?

    clinically and cost-effective timing and dose of a single administration of gabapentin to relieve pain in people undergoing surgery...

  15. What is the clinical and cost effectiveness of antidepressants for the management of sciatica?

    knowledge of the potential longer-term harms, and the reclassification of gabapentin and pregabalin as Schedule 3 controlled drugs...